Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Feb 19;7(4):644-647.
doi: 10.1002/ccr3.2027. eCollection 2019 Apr.

Nivolumab and immune-mediated colitis

Heather Walker  1 , Paul Brennan  1   2 , Maximillian Groome  2 , Shaun Walsh  3 , Frank Carey  3
Affiliations
Case Reports

Nivolumab and immune-mediated colitis

Heather Walker et al. Clin Case Rep. .

Abstract

Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.

Keywords: Nivolumab; PD‐1 receptor; immune‐mediated colitis; immune‐regulated adverse events.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests.

Figures

Figure 1
Figure 1
A/B Colonoscopy image displaying: generalized erythematous, friable and edematous mucosa, with the colon and ileal mucosa looking evenly affected with edema and blurring of the normal vascular pattern
Figure 2
Figure 2
Low power slide showing surface epithelium with marked lymphocytic infiltration and underlying collagen membrane
Figure 3
Figure 3
Singular crypt at high magnification demonstrating an apoptotic body (arrowed)
See this image and copyright information in PMC

References

    1. Wolchok JD. PD‐1 blockers. Cell. 2015;162(5):937. - PubMed
    1. Wang PF, Chen Y, Song SY, et al. Immune‐related adverse events associated with anti‐PD‐1/PD‐L1 treatment for malignancies: a meta‐analysis. Front Pharmacol. 2017;8:730. - PMC - PubMed
    1. Wei W, Luo Z. Risk of gastrointestinal toxicities with PD‐1 inhibitors in cancer patients: A meta‐analysis of randomized clinical trials. Medicine (Baltimore). 2017;96(48):e8931. - PMC - PubMed
    1. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD‐1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology. 2017;70(4):558‐567. - PubMed
    1. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune‐related adverse drug reactions of anti‐PD‐1 antibody therapy. Cancer Treat Rev. 2016;45:7‐18. - PubMed

Publication types

LinkOut - more resources